Reply to: 'Comment on Kridin et al.-Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis'
J Eur Acad Dermatol Venereol
.
2024 Apr;38(4):e354-e355.
doi: 10.1111/jdv.19612.
Epub 2023 Nov 14.
Authors
Khalaf Kridin
1
2
3
,
Henner Zirpel
4
,
Noor Mruwat
2
,
Ralf J Ludwig
1
5
,
Diamant Thaci
4
Affiliations
1
Lűbeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
2
Unit of Dermatology and Skin Research Laboratory, Galilee Medical Center, Nahariya, Israel.
3
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
4
Comprehensive Center for Inflammation Medicine, University-Hospital Schleswig-Holstein, Lübeck, Germany.
5
Department of Dermatology, University of Lübeck, Lübeck, Germany.
PMID:
37909324
DOI:
10.1111/jdv.19612
No abstract available
Publication types
Letter
MeSH terms
Biological Products* / adverse effects
Disease Susceptibility / chemically induced
Humans
Psoriasis* / chemically induced
Psoriasis* / drug therapy
Substances
Biological Products